THERAPY DOSSIER · th-316ce13323e4

PKC-zeta specific pseudosubstrate inhibitor (PKCzeta I, Invitrogen)

Drug

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: Wound
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 0

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

No linked human trial in this dataset.

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 28949382 ↗2017Reported benefit

PKCzeta as a promising therapeutic target for TNFalpha-induced inflammatory disorders in chronic cutaneous wounds.

MouseWoundBALB/cMalen = 40 male BALB/c mice in total; groups of n=8 (PBS control, T…Local injection into the skin tissue around the wound20 micromolar PKC-zeta inhibitor in 100 microlitres, co-inj…Delayed, late-phase treatment beginning on day 6 after wounding

Model: Full-thickness excisional cutaneous wound (1.0 x 1.0 cm) on the dorsum, with recombinant murine TNF-alpha injected into the peri-wound tissue to model sustained inflammation

Daily peri-wound TNF-alpha from day 6 delayed wound closure and sustained high IL-8, MCP-1, ICAM-1 and MMP9 expression to day 13, whereas co-administration of the PKC-zeta pseudosubstrate inhibitor attenuated the closure delay and markedly suppressed these mediators. In vitro, PKC-zeta inhibition b…

Extraction: extract · Supplied extraction confidence: 0.85. Machine-extracted fields require source verification.

Loading the evidence…